Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections

• Status: Completed
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF).

Patients scheduled for treatment with intravitreal injections of anti-VEGF will be randomly divided into two groups. In control group no prophylactic medication will be used, whereas in case group one drop of brinzolamide-brimonidine fixed combination will be instilled two hours before the injection. IOP will be measured before the injection, 1 minute after the injection, 10 minutes and 30 minutes post-injection in all eyes. In case group, the pre-injection IOP will be measured prior to the administration of the fixed combination of brinzolamide-brimonidine. The iCare (IC200) tonometer will be used for IOP measurements at all time points.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: General Hospital of Athens Elpis
• Treatments: Brimonidine Tartrate; Brinzolamide

Criteria

Inclusion Criteria:

• Patients scheduled for treatment with intravitreal injections of anti-vascular endothelial growth factors

Exclusion Criteria:

• history of glaucoma or ocular hypertension

• use of topical medications (e.g. IOP-lowering medication, corticosteroids)

• pseudoexfoliation

• pigment dispersion syndrome

• corneal diseases

• active intraocular inflammation

• any intraocular surgery in the last 6 months